Loading...
•
Mar 31, 2020
Eli Lilly Q1 2020 Earnings Report
Eli Lilly's financial performance for Q1 2020 was released, showing a strong increase in revenue driven by volume growth and augmented by COVID-19 related buying patterns, with EPS decreasing on a reported basis but increasing on a non-GAAP basis, and EPS guidance was adjusted.
Key Takeaways
Eli Lilly reported a strong first quarter with a 15% increase in revenue, driven by a 22% increase in volume. The company's performance was augmented by increased customer buying patterns and patient prescription trends due to the COVID-19 pandemic, which added approximately $250 million to revenue. EPS decreased on a reported basis but increased to $1.75 on a non-GAAP basis. The company has adjusted its EPS guidance for 2020.
Revenue increased by 15%, driven by a 22% volume growth, with COVID-19 related buying patterns adding approximately $250 million.
Key growth products launched since 2014 contributed 19 percentage points of revenue growth, representing approximately 51% of total revenue.
Operating expenses grew by 7%, driven by increased investments in R&D.
EPS decreased to $1.60 on a reported basis, but increased to $1.75 on a non-GAAP basis.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Verzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
Eli Lilly has updated its 2020 financial guidance, reflecting both management's expectations for operational performance and the uncertainty surrounding the extent and duration of the impact of the COVID-19 pandemic. Earnings per share for 2020 is now expected to be in the range of $6.20 to $6.40 on a reported basis and $6.70 to $6.90 on a non-GAAP basis.
Positive Outlook
- Increased customer buying patterns and patient prescription trends associated with COVID-19 that were experienced in the first quarter of 2020 will largely be reversed over the course of 2020.
- The reduction in new-to-brand prescription trends will peak in the second quarter of 2020 in the U.S. and much of Europe.
- Healthcare activity, including non-COVID-19 related patient visits with their physicians, will align more closely with historical levels in the second half of 2020.
- Clinical trial enrollment in existing studies, as well as initiation of new clinical trials, will resume in the second half of 2020.
- Investment in COVID-19 related research, testing and support will continue throughout 2020.
Challenges Ahead
- Increased utilization of patient affordability programs will negatively impact U.S. pricing.
- Changes in segment mix due to increased U.S. unemployment will negatively impact U.S. pricing.
- Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity.
- Revenue growth is also expected to be partially offset by a low-single digit net price decline in the U.S., driven primarily by rebates and legislated increases to Medicare Part D cost sharing.
- Net price declines are expected in China, Japan and Europe.